Golf Classic to Benefit St. Jude Children's Research Hospital

San Antonio, Texas (PRWEB) July 09, 2013

Window World TX is once again hosting the 4th annual Window World Cares Charity Golf Classic in San Antonio to benefit St. Jude Children’s Research Hospital! This year’s tournament will be played at the Canyon Springs Golf Club on September 19, 2013.

Window World is a major corporate sponsor of the amazing work performed at St. Jude Children’s Research Hospital. It is the only pediatric cancer research center in the United States where families never pay for treatment that insurance doesn’t cover. To carry out that mission, St. Jude depends on the generosity of its donors and corporate sponsors. Last year’s Window World Cares Charity Golf Classic raised more than $8,500 for St. Jude. This year, Window World TX hopes to eclipse that number by a large margin.

There are several different levels of sponsorships available for the 4th annual Window World Cares Charity Golf Classic. Any donation is appreciated and tax deductible.

To secure a sponsorship for the 4th annual Window World Cares Charity Golf Classic, please contact Rebecca Rowe of Window World TX at 210-767-0995 extension 206 or rrowe(at)windowworldtx(dot)com.

View the original article here

Medrio, a leading EDC company for clinical research, announces his...

San Francisco, CA (press BOX) 10 July 2013

The user experience of technical software is often disappointing, often reflect more as he has made as its use. The Medrio 8.1 presents a new user interface, the workflow-controlled and faster for the user is. "By observing how for new as well as for experienced researchers do their work, it became clear that there were separate data collection and monitoring of workflows that are rarely done at the same time", said Jeff Johnson, Medrios Director of customer experience.

Data entry user must to register patients, see to what data entered at this stage, and respond to requests. Observers, on the other hand need data to see which data needs cleaning, to monitor close queries and forms. Each workflow can be streamlined. The new user interface by 8.1 Medrio is faster and requires less clicks of common tasks is more aesthetically pleasing.

"In addition the Medrio 8.1 fully validated and 21 CFR part 11 compliant data input via iPad leads," said Michael Farr, Medrios Manager of the Medrio scholars. "Although the Medrio not free for commercial trials require 21 CFR part 11 compliance is available, we have found that many do both academics our University customers and commercially sponsored studies and can operate as an EDC for both." Always a student database is as easy as visit enter scholars.medrio.com and an email address. "

"Our research program has the Medrio for less than a year, but has come, depending on the system for a legion of functionality, that we can get uneasy in REDCap. From the forms can easily created or by our other studies on monitoring, reporting and approval processes copied; a very comprehensive solution is all accessible from any computer with a standard Web browser, Medrio. Moreover, thanks to their support and responsiveness it amazingly is free they are, "said Troy Hamilton, clinical research manager Division of Nephrology at the University of Calgary.

About the Medrio, Inc.
Medrio offers an integrated eClinical software as a service (SaaS) platform with a fully hosted electronic data capture (EDC) system, the dramatic study of timelines and costs reduced, by it project managers control over their studies. Enable you studies entirely online will be built without the need for any custom development, Medrio eClinical trials can be ready in days instead of weeks. Medrio was successfully deployed Enterprise studies, registrations and other clinical studies by a number of leading research institutions on contract (CRO), as well as biopharmaceutical and device in phase I-IV. Medrio is free available for investigator-initiated studies that are funded University or Government. Founded in 2005, is headquartered Medrio in the San Francisco Bay area. For more information, visit scholars.medrio.com for more info on Medrios scholars program.

View the original article here

Research Report Breakthrough In The Regulation Of A Key Cancer Drug Target

Main Category: Cancer / Oncology
Also Included In: Biology / Biochemistry;??Genetics
Article Date: 03 Jul 2013 - 1:00 PDT Current ratings for:
Research Report Breakthrough In The Regulation Of A Key Cancer Drug Target

There's not much difference between what makes a man and what makes his beer - at least at the molecular level - according to a new study led by Professor John Schwabe at the University of Leicester.

Scientists used a powerful technique called protein crystallography to look at 3D structures of protein complexes purified from cultured human cells. They discovered that a family of complexes, that switch off gene expression, is regulated by small signalling molecules called inositol phosphates.

This latest study shows that this mode of regulation is conserved from yeast right through to man and is a fundamental process for life.

This discovery is potentially important for developing anti-cancer drugs since these complexes are emerging as effective cancer treatment targets.

The research was funded by the Wellcome Trust and involved collaboration with scientists from the University of Oxford. It was published online ahead of print (July 11) in the journal Molecular Cell.

The importance of this work is emphasised by the award, in November 2012, of ￡2.4 million in the form of a prestigious "Wellcome Trust Senior Investigator Award" to Professor John Schwabe to continue and develop this area of research.

Professor Schwabe said: "Gene regulation is an essential biological process that occurs in every cell in the body to control which proteins are expressed in particular tissues. We have been studying enzymes called Histone Deacetylases (HDACs) that regulate this process. The action of HDACs causes the DNA to become more tightly packaged and thus switches off genes by making them unavailable for expression. HDACs are recruited to DNA by a number of accessory proteins (corepressors) that target the enzyme to the correct gene."

In 2012, the research team announced in Nature that they had discovered a completely new and unexpected mechanism through which one particular HDAC complex (HDAC3 bound to its companion protein SMRT) is regulated.

Professor Schwabe said: "We wanted to ask whether this mode of regulation might apply to other HDAC complexes and be a general principle for HDAC regulation. Now we have taken this investigation several steps forward.

"We have solved the first structure of HDAC1 bound to one of its corepressor proteins (MTA1 - Metastasis-associated protein 1). This new structure allows us to examine how the proteins interact at the atomic level and reveals molecular details that have allowed us to probe the interaction surface.

"We have identified that there is an inositol phosphate-binding site at the interface between the two proteins, and through functional studies, we have confirmed that inositol phosphates are key regulators throughout this class of enzyme.

"This establishes that inositol phosphate regulation is a general paradigm that is conserved from yeast to man. In addition, we have shown that two MTA1 molecules come together to recruit two HDAC enzymes, and we suggest that MTA1 is critical for recruiting HDAC1 to DNA."

Professor Schwabe also emphasised that his research team is very privileged to have secured further funding from the Wellcome Trust to support this programme of research for the next 7 years: "We expect to gain an in depth insight into the role of inositol phosphates in the regulation of class I histone deacetylases and the specificity conferred to histone deacetylases by their recruitment into large multi protein complexes".

The research team used a cutting edge technique (protein crystallography) to look at the 3D structure of proteins involved in gene regulation. They optimised the conditions needed to grow microcrystals and took these to the UK's powerful synchrotron (Diamond Light Source, Oxford) to obtain diffraction data. These data are used to build images of the proteins, and for the first time, the team has been able analyse how the proteins interact with each other.

"With this new level of molecular detail we are exploring the design of novel HDAC inhibitors to target of the HDAC-corepressor interface. These may provide the foundation for future drug development and may lead to new anti-cancer therapies".

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject. The University of Leicester team consisted of: Dr. Chris Millard, Dr. Peter Watson, Dr. Louise Fairall and Professor John Schwabe at the Biochemistry Department. The research involved a collaboration with Professor Dame Carol Robinson and Dr. Yuliya Gordiyenko at the Chemistry Department, University of Oxford.

University of Leicester

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Leicester. "Research Report Breakthrough In The Regulation Of A Key Cancer Drug Target." Medical News Today. MediLexicon, Intl., 3 Jul. 2013. Web.
5 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'Research Report Breakthrough In The Regulation Of A Key Cancer Drug Target'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

ABC2-Funded Research Featured in Scientific American

ABC2-Funded Research Featured in Scientific American | Accelerate Brain Cancer Cure jQuery(document).ready(function(){ if(jQuery('#region-sidebar-first ul.menu li a.active')){ jQuery('#region-sidebar-first ul.menu li a.active').parent().append(''); } }); Skip to main content Accelerate Brain Cancer Cure

DONATE NOW

Get InformedBrain Tumor FactsClinical TrialsNewsVideosSmarter ResearchWhat We FundHow We FundWho We FundScientific GatheringsGet InvolvedWays To GiveJoin An EventPersonal FundraisingAbout UsOur StoryOur TeamOur PartnersTHROUGH OUR EYES ABC2-Funded Research Featured in Scientific American Article | January 31, 2013

Brain cancer research funded by Accelerate Brain Cancer Cure is featured in Scientific American today.

The research involves a multi-center clinical study?using new exosomal diagnostic tests developed by New York City-based Exosome Diagnostics to identify a genetic mutation found exclusively in glioma, the most common form of brain cancer.??

Brain tumor cells shed micro-vesicles, called exosomes, into cerebral spinal fluid, blood, and urine.?This new method of testing?could potentially detect and monitor the progression of a wide variety of cancers and eliminate the need for painful and sometimes life-threatening biopsies.?

Read the full article in Scientific American.

Learn more about the exosome project and other brain cancer research funded by Accelerate Brain Cancer Cure.

Main Image Credit:?Scientific AmericanNewsletter Issue:?February 2013 Share| More News April 2, 2013 10:00 AM White House Announces BRAIN Initiative The BRAIN Initiative Challenges Researchers to Unlock Mysteries of Human Mind. February 20, 2013 02:32 PM Improving The Lives Of Those Affected By Brain Tumors Ashley Varner guest blogs about her social work pilot study on the lived experience of family members who live with someone diagnosed with a primary malignant brain tumor. February 1, 2013 06:12 PM Low Grade Glioma Research Workshop In partnership with UCSF and MD Anderson, ABC2 brought together researchers from leading medical centers and biotech companies to strategize new therapeutic paths to treat Low Grade Gliomas. Join us in our fight for a cure! This form needs Javascript to display, which your browser doesn't support. Sign up here insteadTo sign up to receive our emails, fill in the following fields and hit submit. Thanks, and welcome!first namelast name* email* required ? Links HomeDonateGet InformedSmarter ResearchGet InvolvedAbout us Get Involved DonateWays to GiveJoin an EventPersonal Fundraising Twitter Connect With Us Contact UsGet in touch with usFacebookMeet new friends and join the discussion in FacebookTwitterTweet and follow us. News, press & infoRSS Feeds Subscribe to News Copyright 2011 ABC2 All Rights Reserved.Privacy Policy

View the original article here

Low Grade Glioma Research Workshop

Low Grade Glioma Research Workshop jQuery(document).ready(function(){ if(jQuery('#region-sidebar-first ul.menu li a.active')){ jQuery('#region-sidebar-first ul.menu li a.active').parent().append(''); } }); Skip to main content Accelerate Brain Cancer Cure

DONATE NOW

Get InformedBrain Tumor FactsClinical TrialsNewsVideosSmarter ResearchWhat We FundHow We FundWho We FundScientific GatheringsGet InvolvedWays To GiveJoin An EventPersonal FundraisingAbout UsOur StoryOur TeamOur PartnersTHROUGH OUR EYES Low Grade Glioma Research Workshop Article | February 01, 2013

In partnership with UCSF and MD Anderson, Accelerate Brain Cancer Cure brought together researchers from leading medical centers and biotech companies to strategize new therapeutic paths to treat Low Grade Gliomas.? The January research workshop, which was held in San Francisco, focused on understanding the underlying biology of brain tumors such as oligodendrogliomas and astrocytomas.

A primary area of focus at the meeting was around identifying key genetic mutations such as IDH, which might present an opportunity for a therapeutic intervention.? IDH mutations are found in about 70% of lower grade brain tumors and are thought to play a role in cancer metabolism. The research group discussed the potential of inhibiting IDH as a way to slow the progression of tumors where the gene alteration is present.

Beyond the development of specific drugs to treat low grade gliomas, the workshop explored the unique challenges of designing clinical trials for glioma.? The use of imaging as a means to determine if a drug is efficacious was one promising technology platform featured at the workshop.? With newer more refined imaging capabilities, oncologists might be able to see changes at the cellular level and indications of response as patients are given a particular drug.

The research workshop included participation from UCSF, MD Anderson, Memorial Sloan Kettering, Vancouver General Hospital, Massachusetts General Hospital, Johns Hopkins, UCLA, Novartis, Agios, and others.

The complete agenda for the meeting can be viewed here.

Newsletter Issue:?February 2013 Share| More News April 2, 2013 10:00 AM White House Announces BRAIN Initiative The BRAIN Initiative Challenges Researchers to Unlock Mysteries of Human Mind. February 20, 2013 02:32 PM Improving The Lives Of Those Affected By Brain Tumors Ashley Varner guest blogs about her social work pilot study on the lived experience of family members who live with someone diagnosed with a primary malignant brain tumor. January 31, 2013 08:48 PM ABC2-Funded Research Featured in Scientific American The collaboration between academic and industry researchers aims to develop a test to detect genetic brain tumor mutations in cerebral spinal fluid and blood.??? Join us in our fight for a cure! This form needs Javascript to display, which your browser doesn't support. Sign up here insteadTo sign up to receive our emails, fill in the following fields and hit submit. Thanks, and welcome!first namelast name* email* required ? Links HomeDonateGet InformedSmarter ResearchGet InvolvedAbout us Get Involved DonateWays to GiveJoin an EventPersonal Fundraising Twitter Connect With Us Contact UsGet in touch with usFacebookMeet new friends and join the discussion in FacebookTwitterTweet and follow us. News, press & infoRSS Feeds Subscribe to News Copyright 2011 ABC2 All Rights Reserved.Privacy Policy

View the original article here

Additional Research on Menopausal Hormone Therapy and Breast Cancer

A recent study of menopausal hormone therapy and risk of breast cancer reported that risk may vary by body weight and the type of hormone therapy. These results were published in Cancer Epidemiology, Biomarkers, & Prevention.

As women reach menopause and beyond, more than 80% will experience symptoms such as hot flashes, night sweats, sleep disturbance, and vaginal dryness. Estrogen, with or without progestin, is an effective treatment for many of these symptoms. Over the last several years, however, studies have raised important concerns about the health effects of menopausal hormone therapy.

Use of estrogen plus progestin has been linked with an increased risk of heart disease, breast cancer, stroke, and blood clots and a decreased risk of fractures and colorectal cancer. Use of estrogen alone, which is generally reserved for women who have had a hysterectomy, has been linked with an increased risk of strokes and a decreased risk of fractures.

Although it is now well established that menopausal hormone therapy with estrogen plus progestin increases the risk of breast cancer, researchers continue to explore the question of which subgroups of women are at greatest risk. This information would help personalize messages about the risks and benefits of hormone therapy.

The current study evaluated information from the California Teachers Study. Of the more than 56,000 perimenopausal or postmenopausal women in the study, 2,857 developed invasive breast cancer during 10 years of follow-up.

Compared with women who had never used hormone therapy, women who had used estrogen alone for 15 years or longer had a 19% increased risk of breast cancer (A 19% increase in risk means that if a woman has a 5% risk of getting breast cancer in the next 20 years, the risk goes up to 6%.). Women who had used estrogen plus progestin for 15 years or longer had an 83% increased risk of breast cancer (An 83% increase means that if a woman has a 5% risk over 20 years, the risk goes up to approximately 9%).For users of estrogen plus progestin, risk varied by the specific type of regimen used. Continuous regimens (progestin every day of the month) appeared to increase breast cancer risk to a greater extent than sequential regimens (progestin only some days of the month).The increased risk of breast cancer among users of hormone therapy was most apparent among thinner women.Use of hormone therapy increased the risk of cancers that were estrogen receptor-positive and progesterone receptor-positive.

These results provide additional evidence regarding the links between menopausal hormone therapy and risk of breast cancer. Women who are considering hormone therapy to manage menopausal symptoms are advised to talk with their doctor about the risks and benefits.

Reference: Saxena T, Lee E, Henderson K et al. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiology, Biomarkers, & Prevention [early online publication]. August 10, 2010.

View the original article here